Valuation: BioAge Labs, Inc.

Market Cap 1.01B 886M 818M 754M 1.42B 97.65B 1.45B 9.77B 3.84B 47.82B 3.81B 3.72B 165B P/E 2026 *
-16.4x
P/E 2027 * -13.9x
Enterprise Value 741M 647M 597M 551M 1.04B 71.32B 1.06B 7.14B 2.81B 34.93B 2.78B 2.72B 120B EV / Sales 2026 *
13.6x
EV / Sales 2027 * 18.9x
Free-Float
97.56%
Yield 2026 *
-
Yield 2027 * -
1 day+2.93%
1 week-6.29%
Current month-6.94%
1 month+14.11%
3 months+23.36%
6 months+13.14%
Current year+72.41%
1 week 21.36
Extreme 21.36
23.87
1 month 20.61
Extreme 20.6061
25.96
Current year 11.87
Extreme 11.8665
25.96
1 year 4.11
Extreme 4.11
25.96
3 years 2.88
Extreme 2.88
26.62
5 years 2.88
Extreme 2.88
26.62
10 years 2.88
Extreme 2.88
26.62
Manager TitleAgeSince
Chief Operating Officer 43 30/04/2020
Chief Executive Officer 43 31/03/2015
Director of Finance/CFO 58 31/10/2021
Director TitleAgeSince
Director/Board Member 43 31/03/2015
Director/Board Member 43 31/05/2017
Director/Board Member 55 31/05/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Principal Accounting Officer

60,648 0.1364%
10/06/26 Free

Director

22,000 0.0495%
10/06/26 Free

Director

22,000 0.0495%
Change 5-day change 1-year change 3-year change Capi.($)
+2.93%-6.29%+375.21% - 1.01B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.46%-0.60%+239.99%+179.48% 20.72B
Weighted average by Cap. +0.25%+0.32%+172.51%+187.42%

Financials

2026 *2027 *
Net sales 54.29M 47.45M 43.78M 40.36M 76.07M 5.23B 77.76M 523M 206M 2.56B 204M 199M 8.82B 35.42M 30.95M 28.56M 26.33M 49.62M 3.41B 50.73M 341M 134M 1.67B 133M 130M 5.75B
Net income -58.37M -51.01M -47.07M -43.39M -81.78M -5.62B -83.59M -563M -221M -2.75B -219M -214M -9.48B -80.42M -70.27M -64.85M -59.77M -113M -7.74B -115M -775M -305M -3.79B -302M -295M -13.06B
Net Debt -273M -239M -220M -203M -383M -26.32B -391M -2.63B -1.04B -12.89B -1.03B -1B -44.38B -346M -302M -279M -257M -484M -33.29B -495M -3.33B -1.31B -16.3B -1.3B -1.27B -56.13B
Logo BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Employees
61
Date Price Change Volume
17/07/26 US$22.81 +2.93% 458,708
16/07/26 US$22.16 -2.38% 528,264
15/07/26 US$22.70 -0.35% 513,095
14/07/26 US$22.78 +4.57% 500,401
13/07/26 US$21.79 -10.50% 548,913
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
22.81USD
Average target price
49.50USD
Spread / Average Target
+117.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BIOA Stock